Animesh Sinha, MD
Dermatology · Williamsville, NYNPI 1285733014
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Argenx US, Inc. at 51.5% of the total.
Across 51 payments — averaging $224.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$6K
- Revvity, Inc.$3K
- Almirall LLC$800
- Incyte Corporation$715
- Sanofi$158
- Lilly USA, LLC$155
- plus $737 from 11 others
Across 99 payments — averaging $4064.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$330K
- LEO Pharma AS$42K
- Hoffmann-la Roche Limited$15K
- UCB SA$9K
- Novartis$6K
What the payments were for
- Consulting fees$6,42556%
- Speaking & faculty fees$3,00026%
- Food & beverage$1,95917%
- Education$901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 7 | $5,908 |
| Revvity, Inc. | 1 | $3,000 |
| Almirall LLC | 1 | $800 |
| Incyte Corporation | 10 | $715 |
| Sanofi | 3 | $158 |
| Lilly USA, LLC | 6 | $155 |
| AbbVie | 7 | $154 |
| Pfizer | 1 | $133 |
| LEO Pharma Inc. | 1 | $111 |
| Sun Pharmaceutical Industries Inc. | 3 | $111 |
| Novartis | 4 | $82 |
| Arcutis Biotherapeutics, Inc. | 2 | $62 |
| Galderma Laboratories, L.p. | 1 | $20 |
| UCB, Inc. | 1 | $18 |
| Medtronic | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$5,625
- Anti-BP180-NC16A-4X ELISA (IgG)$3,000
- Anti-Desmoglein 1 ELISA (IgG)$3,000
- Anti-BP230-CF ELISA (IgG)$3,000
- OPZELURA$345
- DUPIXENT$133
- VYVGART HYTRULO$122
How this compares
$11,474 in reported general payments places this provider in the 75th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BivigamImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $264,749 |
| Mycophenolate Mofetil | 11 | $311 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Williamsville
- Michael NazarethWilliamsville$849K
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.